Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived inhibitory antibody that can specifically target mouse CD8 molecules and deplete CD8 T cells, and is mainly applicable to research in fields such as cancer, inflammation, immunology, and metabolic diseases.

Anti-Mouse CD8 Antibody (HB-129), at a dose of 200 μg administered intraperitoneally once a week starting from day 8, can reduce the anti-tumor effect of Dasatinib in the P815 tumor mouse model [1].
In the mouse model of granulomatous experimental autoimmune thyroiditis (EAT), administered intraperitoneally (on day 1, day 12, and once every 10 days thereafter), it slightly increases the severity of EAT and inhibits its resolution [2].
In NOD mice undergoing hematopoietic cell transplantation, administered at a dose of 5 μg/g 5 days before transplantation, it can effectively prevent the occurrence of graft-versus-host disease (GVHD) [3].

116-13.1 (HB-129)

Mouse

Monoclonal

Unconjugated